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1. Introduction 
An excess of another aromatic amino acid inhibits 
the incorporation of phenylalanine or tyrosine into 
brain proteins in vivo [ I] and in tissue homogenates 
[2,3] and cell-free preparations [4,5] in vitro. Also 
some other aromatic acids, viz. phenylpyruvate, 
phenyllactate and homogentisate, inhibit in vitro the 
incoporation of phenylalanine, tyrosine and trypto- 
phan into brain proteins [6] . This latter study 
suggested that the formation of aminoacyl-tRNAs 
was the step in protein synthesis primarily affected. 
We have now further explored the matter by using 
yeast tRNA mixture or partially purified yeast tRNA 
specific for phenylalanine as the amino acid acceptor, 
and cell-free extract of the calf brain as aminoacyl- 
tRNA synthetase source. 
2. Materials and methods 
Newly removed calf brain was homogenized in 
2 vol. cold 0.05 M Tris-HCl buffer (pH 7.4) contain- 
ing 0.1 M KC1 and 0.012 M MgC12. The suspension 
was centrifuged for 2 h at 105 000 X g. The super- 
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natant was applied to a Sephadex G-l 00 column and 
eluted with the above medium. The first large- 
molecular weight peak was collected and used as 
aminoacyl-tRNA synthetase source. Its protein 
content was determined by the method of Lowry 
et al. [7]. It was stored in small portions at -20°C 
before use. The mixed tRNA fraction used was Sigma 
(type III) No. R-7 125 and the yeast t RNA specific 
for phenylalanine that of Sigma (type V) No. R-3001. 
The standard incubation mixture was that of Chou 
et al. [8]. It contained in total 1.0 ml vol. 200 gmol 
Tris-HCl (pH 7.8), 20 pmol KCl, 20 pmol MgClz , 
8 pmol ATP, 0.8 pmol CTP, 7 pmol 2-mercaptoethanol, 
5 pmol creatine phosphate and 10 pg creatine kinase. 
It was supplemented with the indicated amounts of 
the above aminoacyl-tRNA synthetase solution, 
tRNA from yeast and with L-[G-3H]phenylalanine, 
L-[G-3H]tyrosine of L-[G-3H]tryptophan (4 &i, 
Amersham, spec. act. 1 .O kCi/mol, concentration 
ranges from 25-500 PM). The reaction mixtures were 
incubated at 37°C for 30 min during which time the 
rate of formation of aminoacyl-tRNAs was almost 
constant. Some incubations were performed with an 
excess (2 mM) of one of the other aromatic amino 
acids or with one of the following aromatic acids: 
homogentisic, phenylpyruvic, phenyllactic, phenyl- 
acetic, salicylic or benzoic acid. The reactions were 
stopped by adding 2 ml 67% (w/v) ethanol (at -20°C) 
containing 0.5 M NaCl and 0.1% (w/v) unlabelled 
North-Holland Publishing Company - Amsterdam 
Volume 8 1, number 1 FEBS LETTERS September 1977 
phenylalanine, tyrosine or tryptophan, respectively. 
The aminoacyl-tRNA samples were prepared accord- 
ing to Fangman and Neidhardt [9] . All the samples 
were dissolved in 1 .O M NaOH and their radioactivity 
was determined as described by LghdesmCki and Oja 
PA. 
3. Results and discussion 
Only phenylpyruvate and homogentisate signifi- 
cantly inhibited the incorporation of phenylalanine, 
tyrosine or tryptophan into yeast tRNA (table 1). 
When yeast tRNA specific for phenylalanine was 
used tyrosine also significantly inhibited the forma- 
tion of phenylalanyl-tRNA. The inhibitory effects 
were quantitatively identical even when the experi- 
ments were carried out with a higher amount (50 g/l 
protein) of brain extract as aminoacyl-tRNA synthe- 
tase. Yeast tRNA can readily replace endogenous 
tRNA, since our previous results with endogenous 
tRNA synthetase fractions from the rat brain were 
qualitatively very similar [6] . Linear plots indicated 
that incorporation of aromatic amino acids into the 
respective tRNAs appeared to obey simple Briggs- 
Haldane kinetics within the concentration range 
studied, as shown in fig.1 for tRNA specific for 
phenylalanine, for example. The apparent Km and I/ 
constants were determined from unweighted data in 
S/v versus S plots. In most cases both K, and I/ were 
diminished in the presence of homogentisate or 
phenylpyruvate (table 2), suggesting an inhibition of 
the uncompetitive type. Only in the charging of 
tRNA specific for phenylalanine did phenylpyruvate 
elevate Km and homogentisate reduce V, rendering 
competitive and mixed inhibition possible respec- 
Table 1 
Inhibition provoked by the excess of a second aromatic amino acid or some other aromatic acid in the 
incorporation of [3H]phenylalanine, [‘Hltyrosine and [‘Hltryptophan into the respective tRNAs 
isolated from yeast 
Relative rate of incorporation into aminoacyl-tRNA 
Inhibitor 
(2 mM) 
[‘HI Phenylalanine [3H]Tyrosine [aH]Tryptophan 
- tRNA mixture tRNA mixture 
tRNA mixture tRNA specific for 
(%I phenylalanine (%) (%) (%I 
None 
Phenylalanine 
Tyrosine 
Tryptophan 
Homogentisate 
Phenylpyruvate 
Phenyllactate 
Phenylacetate 
Salicylate 
Benzoate 
100.0 f 5.9 
83.8 * 10.0 
86.1 f 9.9 
49.2 f 2.6a 
61.6? 8.2a 
82.7 * 8.3 
92.2 f 14.6 
91.9 t 8.5 
106.4 2 9.2 
(7) 
100.0 A 7.0 100.0 t 8.1 
95.2 + 8.7 
77.8 f 6.6b 
88.3 + 7.7 103.7 + 4.7 
28.1 f 4.5a 51.8? 5.2a 
75.3 f 6.7b 71.0 r 15.6b 
101.3 + 7.9 84.2 + 9.3 
99.4 + 4.8 
101.9 * 10.5 
96.8 + 9.3 
(6) (6) 
100.0 + 8.0 
95.6 -f 10.4 
82.2? 9.2 
61.5 -r 9.2a 
62.6 + 7.6a 
98.6 2 11.6 
100.4 * 7.1 
82:5 + 9.6 
97.8 f 11.8 
(6) 
Significant differences from control: 
a P < 0.01 
b P < 0.05 
Number of experiments in parentheses 
Standard incubation mixture, as described in Materials and methods, was incubated at 37°C for 30 min with 
1 g/l yeast tRNA mixture, or 40 mg/l yeast tRNA specific for phenylalanine, cell-free extract of calf brain 
(7.6 g/l protein), 0.5 mM [‘HI phenylalanine, [$H] tyrosine or [‘HI tryptophan (4 mCi/l) and the inhibitor 
under investigation. Results (means f SEM) are given as percentages of the corresponding control incubations 
without the inhibitor 
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Fig.1. Inhibition of incorporation of [3H]phenylalanine into 
yeast tRNA specific for phenylalanine by 2 mM homogenti- 
sate (u) and phenylpyruvate (o) as a function of phenyl- 
alanine concentration. Control incubations (0) were carried 
out without inhibitor. S, phenylalanine concentration (mM) 
and v, velocity (nmol s-’ kg protein-l ). Each point is the 
mean of five or six experiments. SEM are indicated by 
vertical bars. 
tively. In general, homogentisate was a more potent 
inhibitor than phenylpyruvate. 
The predominantly uncompetitive type of inhibi- 
tion suggests that phenylpyruvate and homogentisate 
may reversibly combine with an aromatic amino acid- 
aminoacyl-tRNA synthetase complex and prevent its 
further reaction with tRNA. Inhibition of formation 
of aminoacyl-tRNAs may not, however, be the only 
mechanism by which phenylalanine and homo- 
gentisate bring about a strong inhibition of the 
whole process of protein synthesis [lo] . The later 
translational steps are probably also affected [6] . 
An excess of phenylalanine - a greater concentration 
than tested in the present study - similarly affects 
both the formation of aminoacyl-tRNAs and the 
subsequent incorporation of amino acids into protein 
in the brain [ 1 l] , even if in human leucocytes only 
the translational processes eem to be inhibited [ 121 . 
There may be up to 6 mM phenylalanine and 
about 0.1 mM phenylpyruvate in blood plasma of 
untreated patients suffering from phenylketonuria 
[ 131. In alkaptonuria the concentration of homo- 
gentisate is about 0.2 mM [ 141 . The plasma levels 
do not reflect tissue concentrations correctly, how- 
ever, since the metabolites of phenylalanine and 
tyrosine are effectively excreted in these diseases; 
the daily output of homogentisate in urine may 
amount to 50 mmol in alkaptonuria [ 141, and 
30 mmol phenylpyruvate and 10 mmol phenyllactate 
may be excreted in phenylketonuria [ 131. Owing to 
tubular reabsorption the daily loss of phenylalanine 
in urine in phenylketonuria is maximally only 5 
mmol. It is thus not exactly known how much 
phenylalanine, phenylpyruvate, phenyllactate or 
homogentisate there is in brain tissue in human 
patients, but at least in animals the concentration of 
phenylalanine in the brain can be increased up to 
the mM range in experimental hyperphenylalaninaemia 
[l] . Then phenylalanine metabolites also accumulate 
in the brain [ 151, apparently mainly due to the 
action of brain phenylalanine aminotransferase 
(EC 2.6.1 S) [ 161. In alkaptonuria there is obviously 
not any excess amino acid in the brain nor is the 
formation of homogentisate from tyrosine enhanced 
in situ. Consequently, in contrast to phenylketonuria, 
no major brain damage occurs in alkaptonuria. 
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